Summary
This report contains a summary of the analyst consensus forecasts available in the publisher's Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 29 drugs indicated for COVID-19 which have analyst consensus forecasts available.
Scope
This 41-page report gives important, expert insight you won’t find in any other source. 14 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
Reasons to Buy
This report contains a summary of the analyst consensus forecasts available in the publisher's Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 29 drugs indicated for COVID-19 which have analyst consensus forecasts available.
Scope
This 41-page report gives important, expert insight you won’t find in any other source. 14 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -
- Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the COVID-19 disease space
- Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space
Reasons to Buy
- Analysis of COVID-19 analyst consensus sales forecasts
- Overview of Pipeline portfolio of companies involved in COVID-19 disease space
- Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs
Table of Contents
1 COVID-19 Global Analyst Consensus Sales Forecast
2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts
3 BioNTech SE
4 Moderna
5 Novavax Inc
6 Inovio
7 Gilead Sciences
9 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Arcturus Therapeutics Ltd
- Atossa Therapeutics Inc
- CanSino Biologics Inc
- ContraFect Corp
- CTI BioPharma Corp
- CureVac NV
- Dynavax Technologies Corp
- Eiger BioPharmaceuticals Inc
- Eli Lilly and Co
- Enlivex Therapeutics Ltd
- Evelo Biosciences Inc
- Genexine Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Heat Biologics Inc
- I-Mab
- Immunome Inc
- InflaRx NV
- Inovio Pharmaceuticals Inc
- Kiniksa Pharmaceuticals Ltd
- Moderna Inc
- Molecular Partners AG
- Novavax Inc
- Pfizer Inc
- Regeneron Pharmaceuticals Inc
- Shionogi & Co Ltd
- TFF Pharmaceuticals Inc
- Vir Biotechnology Inc
